AQR Capital Management
NAVB

AQR Capital Management’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

AQR Capital Management’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,455
Closed -$47K – 2309
2015
Q2 		$47K Hold
1,455
– – ﹤0.01% 2197
2015
Q1 		$46K Hold
1,455
– – ﹤0.01% 2122
2014
Q4 		$55K Hold
1,455
– – ﹤0.01% 2482
2014
Q3 		$38K Sell
1,455
-1,930
-57% -$51.1K ﹤0.01% 2490
2014
Q2 		$100K Hold
3,385
– – ﹤0.01% 2459
2014
Q1 		$125K Hold
3,385
– – ﹤0.01% 2497
2013
Q4 		$140K Sell
3,385
-22
-0.6% -$861 ﹤0.01% 2480
2013
Q3 		$181K Hold
3,407
– – ﹤0.01% 2361
2013
Q2 		$182K Buy
+3,407
New +$170K ﹤0.01% 2227

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AQR Capital Management's NAVB Position: Q3 2015 in Review

AQR Capital Management sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2015, closing a stake of 1,455 shares — an estimated $47K sold.

AQR Capital Management first reported a position in NAVB in Q2 2013 and held it in 9 quarters. The position peaked at $182K in Q2 2013. 81 funds tracked by Wall St. Rank hold NAVB as of Q3 2015.

  • AQR Capital Management reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2015 after selling out during the quarter.
  • AQR Capital Management sold 1,455 Navidea Biopharmaceuticals Inc. shares in Q3 2015, an estimated $47K.
  • AQR Capital Management first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 9 quarters.
  • AQR Capital Management's Navidea Biopharmaceuticals Inc. position peaked at $182K in Q2 2013.
  • 81 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2015.

Based on AQR Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.